|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | A61K 31/517 | |
| A61K 31/282 | |||
| A61K 31/555 | |||
| A61K 33/24 | |||
| A61K 41/00 | |||
| A61P 35/00 |
| (11) | Patento numeris | 1648465 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 04743275.2 |
| Europos patento paraiškos padavimo data | 2004-07-07 | |
| (97) | Europos patento paraiškos paskelbimo data | 2006-04-26 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2010-08-25 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/GB2004/002932 |
| Data | 2004-07-07 |
| (87) | Numeris | WO 2005/004870 |
| Data | 2005-01-20 |
| (30) | Numeris | Data | Šalis |
| 0316176 | 2003-07-10 | GB | |
| 0406546 | 2004-03-24 | GB | |
| 0407753 | 2004-04-06 | GB |
| (72) |
WEDGE, Stephen Robert, AstraZeneca R & D Alderley, GB
RYAN, Anderson Joseph, AstraZeneca R & D Alderley, GB
|
| (73) |
AstraZeneca AB,
151 85 Södertälje,
SE
|
| (54) | USE OF THE QUINAZOLINE DERIVATIVE ZD6474 COMBINED WITH PLATINUM COMPOUNDS AND OPTIONALLY IONISING RADIATION IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS AND/OR INCREASED VASCULAR PERMEABILITY |
| USE OF THE QUINAZOLINE DERIVATIVE ZD6474 COMBINED WITH PLATINUM COMPOUNDS AND OPTIONALLY IONISING RADIATION IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS AND/OR INCREASED VASCULAR PERMEABILITY |